Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. Among authors: themeli m. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Drent E, et al. Among authors: themeli m. Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858358 Free PMC article.
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ. Frerichs KA, et al. Among authors: themeli m. Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Expert Rev Clin Immunol. 2018. PMID: 29465271 Review.
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Holthof LC, van der Schans JJ, Katsarou A, Poels R, Gelderloos AT, Drent E, van Hal-van Veen SE, Li F, Zweegman S, van de Donk NWCJ, Themeli M, Groen RWJ, Mutis T. Holthof LC, et al. Among authors: themeli m. Clin Cancer Res. 2021 Jul 1;27(13):3793-3803. doi: 10.1158/1078-0432.CCR-20-2188. Epub 2021 Apr 21. Clin Cancer Res. 2021. PMID: 33883175
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, Patankar YR, Merino E, Reijmers RM, Frerichs KA, Yuan H, de Bruijn J, Stroopinsky D, Avigan D, van de Donk NWCJ, Zweegman S, Mutis T, Sadelain M, Groen RWJ, Themeli M. Katsarou A, et al. Among authors: themeli m. Sci Transl Med. 2021 Dec 8;13(623):eabh1962. doi: 10.1126/scitranslmed.abh1962. Epub 2021 Dec 8. Sci Transl Med. 2021. PMID: 34878825 Free PMC article.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. Among authors: themeli m. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138.
van der Schans JJ, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, Baardemans T, Yuan H, de Bruijn J, Zweegman S, van de Donk NWCJ, Groen RWJ, Themeli M, Mutis T. van der Schans JJ, et al. Among authors: themeli m. Clin Cancer Res. 2023 Oct 13;29(20):4219-4229. doi: 10.1158/1078-0432.CCR-23-0132. Clin Cancer Res. 2023. PMID: 37527004
40 results